News Image

ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations

By Mill Chart

Last update: Dec 4, 2023

In this article we will dive into ALKERMES PLC (NASDAQ:ALKS) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ALKERMES PLC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

A Deep Dive into ALKERMES PLC's Growth Metrics.

  • In terms of Return on Equity(ROE), ALKERMES PLC is performing well, achieving a 15.85% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
  • ALKERMES PLC has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
  • ALKERMES PLC has achieved significant 1-year revenue growth of 40.56%, signaling its ability to capture market opportunities and drive top-line expansion. This growth indicates the company's effective execution and its potential for continued success.
  • ALKERMES PLC has demonstrated strong quarter-to-quarter (Q2Q) revenue growth of 50.91%, reflecting its ability to generate consistent increases in sales. This growth highlights the company's effective market positioning and its potential for continued success.
  • ALKERMES PLC has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
  • The free cash flow (FCF) of ALKERMES PLC has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
  • ALKERMES PLC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 3.0K% increase. This indicates improving financial performance and the company's effective management of its operations.
  • The average next Quarter EPS Estimate for ALKERMES PLC has experienced a 7.33% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
  • The quarterly earnings of ALKERMES PLC have shown a 3.0K% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • accelerating EPS growth for ALKERMES PLC: the current Q2Q growth of 3.0K% exceeds the previous year Q2Q growth of -85.71%.

What is the full fundamental picture of NASDAQ:ALKS telling us.

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

ALKS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 610 industry peers in the Biotechnology industry. ALKS has an average financial health and profitability rating. ALKS has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make ALKS a good candidate for value and growth investing.

Our latest full fundamental report of ALKS contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.


This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.



NASDAQ:ALKS (4/22/2024, 7:00:00 PM)

After market: 24.07 0 (0%)


+0.22 (+0.92%)


News Image3 days ago - Market News VideoFirst Week of June 21st Options Trading For Alkermes (ALKS)
News Image5 days ago - Alkermes plcAlkermes to Report First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...

News Image6 days ago - ChartmillInvestors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.

News Image11 days ago - Market News VideoOversold Conditions For Alkermes (ALKS)
News Image13 days ago - ChartmillExploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).

ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.

News Image15 days ago - Alkermes plcAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...

News Imagea month ago - Market News VideoNoteworthy Tuesday Option Activity: ALKS, DKNG, VRT
News Imagea month ago - Market News VideoFirst Week of ALKS November 15th Options Trading
News Image2 months ago - Alkermes plcAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...

News Image2 months ago - Investor's Business DailyAmicus Therapeutics Stock Sees RS Rating Improve To 74

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

News Image2 months ago - Investor's Business DailyBeam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

News Image2 months ago - Investor's Business DailyAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

ALKS Links
Follow us for more